

Real Time Material Information

This information is provided by 3176 Medigen Biotech Corp. (TPEX Listed Company)

Item	1	Announcement Date	2021/03/25	Announcement Time	17:06:27
Spokesperson	Arlene Chiang	Spokesperson Position	Assistant Vice President, Operations Department	Contact Information	[02]2653-5200#890
Subject	The Company has received approval letter from the Taiwan Ministry of Health and Welfare (MOHW) for the joint autologous NK cell therapy project with the Jen-Ai Hospital Dali Branch				
Pursuant To Article	4	Subparagraph	53	Date of occurrence of event	2021/03/25
Details	<p>1. Date of occurrence of the event: 2021/03/25</p> <p>2. Company name: Medigen Biotechnology Corporation</p> <p>3. Relationship with the Company (please enter "the company itself" or "subsidiaries"): The Company itself.</p> <p>4. Reciprocal shareholding percentage: NA</p> <p>5. Cause of occurrence: The cell processing unit (CPU) within the Company's GTP laboratory is the CPU contracted by the Jen-Ai Hospital Dali Branch in its autologous NK cell (Magicell-NK) therapy project for the treatment of stage IV solid tumors submitted to the MOHW, in compliance with the "Regulation Governing the Application of Specific Medical Examination Technique and Medical Device". The Company has received the approval letter from MOHW on March 25, 2021, confirming that the CPU within the Company's GTP laboratory complies with Good Tissue Practice.</p> <p>6. Countermeasures: Release material information as instructed by the approval letter from MOHW.</p> <p>7. Any other matters that need to be specified:</p> <p>(1) Details on the approved items in the abovementioned Jen-Ai Hospital Dali Branch's cell therapy project:</p> <p>A. Type of cell therapy: Autologous Natural Killer Cell (Magicell-NK)</p> <p>B. Indication: Stage IV solid tumors; Head and Neck Cancer, Lung Cancer, Esophageal Cancer, Gastric Cancer, Liver Cancer (including Bile Duct Cancer), Pancreatic Cancer, Prostate Cancer and Colorectal Cancer.</p> <p>C. Cell Processing Unit: Medigen Biotechnology Corp. Cell Processing Unit</p> <p>D. Effective Period: From 2021/03/25 to 2023/02/02</p> <p>(2) The Company's autologous NK cell therapy project has been approved for use in the following medical institutions: E-Da Cancer Hospital, Hualien Tzu Chi Hospital and Chi Mei Medical Center.</p>				

The above information is declared by the company in accordance with the regulations of the market it belongs to at the time, and released to the public through this system. The company shall hold sole responsibility if any false information is declared.